Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Canadian Oil Sands Limited stock logo
COS
Canadian Oil Sands
C$0.00
C$5.61
C$13.87
N/AN/A2.19 million shsN/A
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
$78.76
-1.1%
$79.30
$64.89
$82.62
$153.58M1.225,472 shs1,925 shs
iCo Therapeutics Inc. stock logo
ICO
iCo Therapeutics
C$0.11
C$0.11
C$0.02
C$0.16
C$952KN/A3.16 million shs1.31 million shs
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$0.07
-4.3%
$0.12
$0.07
$1.42
$2.67M1.973.36 million shs289,116 shs
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
-0.01%+3.04%-1.04%+3.70%+17.94%
iCo Therapeutics Inc. stock logo
ICO
iCo Therapeutics
0.00%0.00%0.00%0.00%0.00%
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
+1.71%-4.80%-40.03%-49.14%+7,729,900.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Canadian Oil Sands Limited stock logo
COS
Canadian Oil Sands
N/AN/AN/AN/AN/AN/AN/AN/A
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
N/AN/AN/AN/AN/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICO
iCo Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Canadian Oil Sands Limited stock logo
COS
Canadian Oil Sands
3.00
BuyC$0.52∞ Upside
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
0.00
N/A$87.3710.93% Upside
iCo Therapeutics Inc. stock logo
ICO
iCo Therapeutics
N/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/A

Current Analyst Ratings

Latest ICO, FAB, SUD, COS, and NBY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
Canadian Oil Sands Limited stock logo
COS
Canadian Oil Sands
Fundamental Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuyC$0.52
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Canadian Oil Sands Limited stock logo
COS
Canadian Oil Sands
N/AN/AN/AN/AN/AN/A
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
N/AN/AN/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICO
iCo Therapeutics
N/AN/AC$0.01 per share8.75C$0.00 per shareN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
$14.73M0.18N/AN/A$0.12 per share0.62

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Canadian Oil Sands Limited stock logo
COS
Canadian Oil Sands
N/AN/A0.00N/AN/AN/AN/AN/AN/A
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
N/AN/A11.74N/AN/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICO
iCo Therapeutics
N/A-C$0.01N/AN/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
-$9.64M-$3.82N/A1.06N/A-65.46%-150.14%-53.48%N/A

Latest ICO, FAB, SUD, COS, and NBY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/26/2024Q4 2023
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A-$0.95-$0.95-$0.57N/A$3.73 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Canadian Oil Sands Limited stock logo
COS
Canadian Oil Sands
N/AN/AN/AN/AN/A
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
$1.481.88%N/AN/AN/A
iCo Therapeutics Inc. stock logo
ICO
iCo Therapeutics
N/AN/AN/AN/AN/A
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/AN/AN/AN/AN/A

Latest ICO, FAB, SUD, COS, and NBY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/20/2024
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
Quarterly$0.24303/21/20243/22/20243/28/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Canadian Oil Sands Limited stock logo
COS
Canadian Oil Sands
N/AN/AN/A
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
N/AN/AN/A
iCo Therapeutics Inc. stock logo
ICO
iCo Therapeutics
N/A
1.14
1.12
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
N/A
1.67
1.00

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Canadian Oil Sands Limited stock logo
COS
Canadian Oil Sands
147,000N/AN/ANot Optionable
First Trust Multi Cap Value AlphaDEX Fund stock logo
FAB
First Trust Multi Cap Value AlphaDEX Fund
147,0001.95 millionN/ANot Optionable
iCo Therapeutics Inc. stock logo
ICO
iCo Therapeutics
N/A9.07 millionN/ANot Optionable
NovaBay Pharmaceuticals, Inc. stock logo
NBY
NovaBay Pharmaceuticals
2436.06 million35.59 millionNot Optionable

ICO, FAB, SUD, COS, and NBY Headlines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Canadian Oil Sands logo

Canadian Oil Sands

TSE:COS
Canadian Oil Sands Limited is a Canada-based investment company. The Company owns a 36.74% interest in the Syncrude Joint Venture (Syncrude), a producer of low sulphur, light, synthetic crude oil (SCO). Syncrude is involved in the mining and upgrading of bitumen from oil sands near Fort McMurray in northern Alberta. The Syncrude Project is comprised of open-pit oil sands mines, utilities plants, bitumen extraction plants and an upgrading complex that processes bitumen into SCO. Syncrude's leases are located in the Athabasca oil sands deposit. Syncrude produces SCO by mining oil sands, extracting the bitumen from the sands, upgrading the recovered bitumen into lighter oil fractions and combining those fractions into a single SCO product.
First Trust Multi Cap Value AlphaDEX Fund logo

First Trust Multi Cap Value AlphaDEX Fund

NASDAQ:FAB
The First Trust Multi Cap Value AlphaDEX Fund (FAB) is an exchange-traded fund that is based on the NASDAQ AlphaDEX Multi Cap Value index. The fund tracks an index that uses fundamental factors to select and weight value stocks from the Nasdaq US Select Indices. FAB was launched on May 8, 2007 and is managed by First Trust.
iCo Therapeutics logo

iCo Therapeutics

CVE:ICO
iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat ocular and infectious diseases. Its in-licensed drug candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat ulcerative colitis and bullous pemphigoid; and Oral AmpB Delivery System, an oral formulation of Amphotericin B that is in Phase 1b clinical trial for the treatment of systemic fungal and parasitic infections. The company was incorporated in 2005 and is headquartered in Vancouver, Canada.
NovaBay Pharmaceuticals logo

NovaBay Pharmaceuticals

NYSE:NBY
NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.